Clover’s protein-based COVID-19 vaccine candidates adjuvanted with either GSK’s pandemic adjuvant system or Dynavax’s CpG 1018 plus alum induced strong neutralizing immune responses in 150 adult and elderly subjects from the Phase 1 clinical study.  Clover’s vaccine candidates both demonstrated a favorable safety and tolerability profile, and have also shown long-term stability at 2-8oC, making them …

Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates Read More »

CEPI to fund the development of Clover’s protein-based S-Trimer vaccine candidate through to licensure, including a global pivotal Phase 2/3 efficacy clinical study beginning before the end of 2020. Agreement between CEPI and Clover anticipates that the vaccine – if proven to be safe and effective – will be made available for procurement and allocation …

CEPI extends partnership with Clover Biopharmaceuticals to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure Read More »

SAB to provide strategic guidance for the global development of Clover’s COVID-19 vaccine program Comprised of prominent vaccine and industry experts from around the world CHENGDU, CHINA, September 25, 2020 – Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, today announced the formation of its Scientific …

Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program Read More »

Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animals and protects nonhuman primates from SARS-CoV-2 challenge  Strong immune response and protection observed with adjuvant systems from GSK and Dynavax led to inclusion of both adjuvants separately into Clover’s ongoing Phase 1 clinical trial of S-Trimer  Clover’s …

Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate Read More »

CEPI to invest an additional $66m upfront in Clover’s S-Trimer protein vaccine candidate. Funding will support clinical development in parallel with scale-up of manufacturing capacity to potentially produce hundreds of millions of doses per year. OSLO, NORWAY, July 8, 2020—CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the expansion of its partnership with Sichuan …

CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate Read More »

150 healthy adult and elderly participants expected to be enrolled in Phase 1 study COVID-19 vaccine candidate to be evaluated in combination with GSK’s pandemic adjuvant system and Dynavax’s CpG 1018 adjuvant following promising preclinical study results Preliminary safety and immunogenicity results expected in August 2020 Global Phase 2b/3 vaccine efficacy study is in planning …

Clover Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate Read More »